Navigation Links
UCB Proudly Reinforces Long-Standing Commitment to Crohn's Disease Community at Digestive Disease Week 2012

ATLANTA, May 18, 2012 /PRNewswire/ -- UCB, Inc., a leading biopharmaceutical company dedicated to the research and development of treatments for severe central nervous system and immunological disorders, is marking Digestive Disease Week (DDW) 2012 in San Diego by reinforcing its commitment to improving the lives of patients with Crohn's disease. UCB will present scientific data at this year's DDW meeting.

"DDW is an exciting opportunity for UCB to join its colleagues in the gastrointestinal community and demonstrate our commitment to improving the lives of patients," said Neil McFarlane, Vice President, Immunology Business Unit, UCB, Inc.  "We are proud to say that UCB's dedication to patients goes beyond the development of effective therapies, but also provides valuable resources and programs to support and unite the Crohn's disease community."

Patient Centricity: The Heart of UCB's Commitment
As a patient-centric global biopharmaceutical leader, UCB transforms the lives of people living with severe diseases through scientific research, advocacy and patient programs.  The company provides support for important patient programs, including:

UCB Crohn's Scholarship Program: Since 2006, UCB has awarded more than 150 scholarships to Crohn's disease patients, totaling $1,620,000.  Scholarship winners must demonstrate academic ambition and the ability to embrace a way of life that overcomes the boundaries of living with Crohn's disease. Through the program, scholarships are awarded to help students continue their education and pursue their goals. Interested candidates will be able to apply for the 2013 scholarship starting in December 2012. & Crohn'sAdvocate: A robust patient resource, takes an all-encompassing approach to connecting, educating and empowering those living with Crohn's disease. Visitors to the site can register for a free magazine, Crohn'sAdvocate, featuring a team of inspiring people living with and beyond Crohn's disease. and Crohn'sAdvocate are designed to connect people on the same journey and break the stigmas associated with Crohn's disease. 

"Get Your Guts in Gear" Official Sponsorship: UCB proudly sponsors this unique program, which brings together cyclists to raise awareness, funds, and provide support for those affected by Crohn's disease.

Crohn's and Colitis Foundation of America Corporate Sponsorship: UCB's ongoing support of the Crohn's and Colitis Foundation of America helps to raise awareness about Crohn's disease, strengthen research efforts, and provide education to patients living with Crohn's disease and Colitis.

For Further Information:
Andrea Levin, Associate Director, U.S. Communications and Public Relations, UCB, Inc.

Dena Koklanaris, Cooney/Waters Group 

About Crohn's Disease
Crohn's disease is a chronic, progressive, destructive disorder that causes inflammation of the gastrointestinal (GI) tract, most commonly at the end of the small intestine (the ileum) and beginning of the large intestine (the colon).  If not effectively treated, it may result in the need for surgery and hospitalization.  Crohn's disease has been estimated to affect more than half a million Americans.  People with Crohn's can experience an ongoing cycle of flare-up and remission throughout their lives.

About UCB
UCB, Brussels, Belgium ( is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8,500 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2011. UCB is listed on Euronext Brussels (symbol: UCB).

Forward Looking Statement
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including estimates of revenues, operating margins, capital expenditures, cash, other financial information, expected legal, political, regulatory or clinical results and other such estimates and results. By their nature, such forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions which could cause actual results to differ materially from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, the inability to obtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects for products in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patent protection for products or product candidates, changes in laws or regulations, exchange rate fluctuations,  changes or uncertainties in tax laws or the administration of such laws and hiring and retention of its employees.  UCB is providing this information as of the date of this press release and expressly disclaims any duty to update any information contained in this press release, either to confirm the actual results or to report a change in its expectations.

There is no guarantee that new product candidates in the pipeline will progress to product approval or that new indications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensing collaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with its products after they are marketed.

Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containment and the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. White Smile Global Inc. Proudly Announces the Introduction of a New Innovative White Smile® Professional™ Dental "In-Office" Teeth Whitening Kit
2. UCB Proudly Reinforces Long-Standing Commitment to Patients and Physicians at American College of Gastroenterology 2011 Annual Scientific Meeting
3. Secretary Reinforces VAs Commitment to Research Safety and Veteran Focus
4. Data Analysis Reinforces the Safety Profile of Levemir(R)
5. Data Presented on Cempra Pharmaceuticals CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates
6. New Data Reinforces the Proven Safety and Effectiveness of the BIRMINGHAM HIP Resurfacing System
7. New Data Reinforces Safety Profile of Abbotts Market-Leading XIENCE V(R) Drug Eluting Stent
8. Analysis of Data Across Multiple Drug Eluting Stent Trials Reinforces Positive Clinical Performance of XIENCE V®
9. Hospira Reinforces Importance of Clinical Surveillance Technology in Line With World Health Day Focus on Antimicrobial Resistance
10. Aptuit Completes Sale of CTS to Catalent; Reinforces Commitment to Scientific Excellence and Most Comprehensive Early to Mid-Phase Development Capability
11. New Analysis Shows Efficacy of REMICADE(R) in Treatment of Ulcerative Colitis in Patients with Recent Disease Onset or Long-Standing Disease
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the European Therapeutic Drug Monitoring (TDM) ... Competitive Intelligence, Emerging Opportunities"  report to ... ) has announced the addition of ...
(Date:11/26/2015)... ) has announced ... High Viscosity Drugs" report to their offering. ... addition of the "Self Administration of High ... --> Research and Markets ( ) ... Administration of High Viscosity Drugs" report to ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "Radioimmunoassay Market by ... (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), ... Global Forecast to 2020" report to ... has announced the addition of the ...
Breaking Medicine Technology:
(Date:11/28/2015)... , ... November 28, 2015 , ... Trying to relax ... created the COUCH BUDDY. "I conceived of this design due to personal experience with ... couch users. It promotes relaxation and convenience, as well as increases support. It also ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published ... Association meeting in Washington D.C. revolved around the fact that proper dental care, both ... talk stressed the link between periodontal disease (more commonly referred to as gum disease) ...
(Date:11/27/2015)... Raleigh, NC (PRWEB) , ... November 27, 2015 , ... ... most effective ways to treat it. Surviving Mesothelioma has just posted the findings ... Researchers at University Hospital Zurich analyzed the cases of 136 mesothelioma patients who were ...
(Date:11/27/2015)... ... November 27, 2015 , ... The print ... USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation ... is distributed nationally, through a vast social media strategy and across a network ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec ... Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end users ... Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership status ...
Breaking Medicine News(10 mins):